《KDOQI慢性肾脏病营养临床实践指南2020更新版》解读

2021-02-08 四川大学华西医院临床营养科 中国全科医学 发表于安徽省

更新指南内容涵盖6个领域:营养评估、医学营养治疗、膳食蛋白质和能量摄入、营养补充剂、微量营养素和电解质。主要包括饮食管理,而不是所有可能的营养干预。

中文标题:

《KDOQI慢性肾脏病营养临床实践指南2020更新版》解读

发布日期:

2021-02-08

简要介绍:

2020年9月,国家肾脏基金会肾病预后质量倡议(KDOQI)发布《KDOQI 慢性肾病营养临床实践指南2020更新版》。20年前KDOQI发布首个终末期肾病患者营养指南,20年来营养管理的新证据不断出现。更新指南不仅包括终末期肾病或晚期慢性肾脏病(CKD)患者,还包括未接受透析的1~5期CKD患者和肾移植患者。更新指南内容涵盖6个领域:营养评估、医学营养治疗、膳食蛋白质和能量摄入、营养补充剂、微量营养素和电解质。主要包括饮食管理,而不是所有可能的营养干预。本文对其中主要内容进行解读,并结合我国实际情况进行讨论。

相关资料下载:
[AttachmentFileName(sort=1, fileName=《KDOQI慢性肾脏病营养临床实践指南2020更新版》解读.pdf)] GetToolGuiderByIdResponse(projectId=1, id=d8a521c0029a8ef5, title=《KDOQI慢性肾脏病营养临床实践指南2020更新版》解读, enTitle=, guiderFrom=中国全科医学, authorId=0, author=, summary=更新指南内容涵盖6个领域:营养评估、医学营养治疗、膳食蛋白质和能量摄入、营养补充剂、微量营养素和电解质。主要包括饮食管理,而不是所有可能的营养干预。, cover=https://img.medsci.cn/20221109/1668021798780_4754896.webp, journalId=0, articlesId=null, associationId=4050, associationName=四川大学华西医院临床营养科, associationIntro=四川大学华西医院临床营养科, copyright=0, guiderPublishedTime=Mon Feb 08 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span class="fontstyle0">2020年9月,国家肾脏基金会肾病预后质量倡议(KDOQI)发布《KDOQI 慢性肾病营养临床实践指南2020更新版》。20年前KDOQI发布首个终末期肾病患者营养指南,20年来营养管理的新证据不断出现。更新指南不仅包括终末期肾病或晚期慢性肾脏病(CKD)患者,还包括未接受透析的1~5期CKD患者和肾移植患者。更新指南内容涵盖6个领域:营养评估、医学营养治疗、膳食蛋白质和能量摄入、营养补充剂、微量营养素和电解质。主要包括饮食管理,而不是所有可能的营养干预。本文对其中主要内容进行解读,并结合我国实际情况进行讨论。</span></p>, tagList=[TagDto(tagId=1821, tagName=营养), TagDto(tagId=2551, tagName=慢性肾病)], categoryList=[CategoryDto(categoryId=14, categoryName=肾内科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=2527, articleKeyword=慢性肾脏病, articleKeywordNum=6, guiderKeywordId=2527, guiderKeyword=慢性肾脏病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2918, appHits=147, showAppHits=0, pcHits=417, showPcHits=2771, likes=2, shares=17, comments=7, approvalStatus=1, publishedTime=Thu Feb 02 13:21:00 CST 2023, publishedTimeString=2021-02-08, pcVisible=1, appVisible=1, editorId=0, editor=QIAN LIN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=5, createdBy=null, createdName=QIAN LIN, createdTime=Mon Jan 30 22:25:43 CST 2023, updatedBy=2427819, updatedName=梁丽玲, updatedTime=Sat Jan 06 00:22:35 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=安徽省, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=《KDOQI慢性肾脏病营养临床实践指南2020更新版》解读.pdf)])
《KDOQI慢性肾脏病营养临床实践指南2020更新版》解读.pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2215683, encodeId=b2a3221568303, content=学习了,很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9c58658087, createdName=ms1000001713362997, createdTime=Thu Jul 18 23:23:24 CST 2024, time=2024-07-18, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2214331, encodeId=9ff22214331ad, content=很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b958459617, createdName=ms1000001318479649, createdTime=Wed Jul 10 22:56:25 CST 2024, time=2024-07-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2214330, encodeId=3edd2214330c9, content=干货!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b958459617, createdName=ms1000001318479649, createdTime=Wed Jul 10 22:56:11 CST 2024, time=2024-07-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2157499, encodeId=4cfe215e499db, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20375727516, createdName=ms5000000109506424, createdTime=Wed Sep 13 11:13:10 CST 2023, time=2023-09-13, status=1, ipAttribution=四川省)]
    2024-07-18 ms1000001713362997 来自福建省

    学习了,很实用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2215683, encodeId=b2a3221568303, content=学习了,很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9c58658087, createdName=ms1000001713362997, createdTime=Thu Jul 18 23:23:24 CST 2024, time=2024-07-18, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2214331, encodeId=9ff22214331ad, content=很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b958459617, createdName=ms1000001318479649, createdTime=Wed Jul 10 22:56:25 CST 2024, time=2024-07-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2214330, encodeId=3edd2214330c9, content=干货!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b958459617, createdName=ms1000001318479649, createdTime=Wed Jul 10 22:56:11 CST 2024, time=2024-07-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2157499, encodeId=4cfe215e499db, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20375727516, createdName=ms5000000109506424, createdTime=Wed Sep 13 11:13:10 CST 2023, time=2023-09-13, status=1, ipAttribution=四川省)]
    2024-07-10 ms1000001318479649 来自广东省

    很棒

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2215683, encodeId=b2a3221568303, content=学习了,很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9c58658087, createdName=ms1000001713362997, createdTime=Thu Jul 18 23:23:24 CST 2024, time=2024-07-18, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2214331, encodeId=9ff22214331ad, content=很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b958459617, createdName=ms1000001318479649, createdTime=Wed Jul 10 22:56:25 CST 2024, time=2024-07-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2214330, encodeId=3edd2214330c9, content=干货!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b958459617, createdName=ms1000001318479649, createdTime=Wed Jul 10 22:56:11 CST 2024, time=2024-07-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2157499, encodeId=4cfe215e499db, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20375727516, createdName=ms5000000109506424, createdTime=Wed Sep 13 11:13:10 CST 2023, time=2023-09-13, status=1, ipAttribution=四川省)]
    2024-07-10 ms1000001318479649 来自广东省

    干货!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2215683, encodeId=b2a3221568303, content=学习了,很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9c58658087, createdName=ms1000001713362997, createdTime=Thu Jul 18 23:23:24 CST 2024, time=2024-07-18, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2214331, encodeId=9ff22214331ad, content=很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b958459617, createdName=ms1000001318479649, createdTime=Wed Jul 10 22:56:25 CST 2024, time=2024-07-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2214330, encodeId=3edd2214330c9, content=干货!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b958459617, createdName=ms1000001318479649, createdTime=Wed Jul 10 22:56:11 CST 2024, time=2024-07-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2157499, encodeId=4cfe215e499db, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20375727516, createdName=ms5000000109506424, createdTime=Wed Sep 13 11:13:10 CST 2023, time=2023-09-13, status=1, ipAttribution=四川省)]
    2023-09-13 ms5000000109506424 来自四川省

    点赞

    0

拓展阅读

Eur Heart J: 打破传统局限!SGLT2 抑制剂 + 非甾体 MRA 联合治疗为慢性肾脏病患者心血管保护提供双重证据

文章内容涵盖了当前临床诊治中的挑战、指南推荐、关键临床试验数据及未来治疗展望,具备较高的临床指导价值。

【今日分享】尿毒清颗粒治疗慢性肾脏病临床应用指南

尿毒清颗粒自上市以来已应用近30年,已被多项指南、诊疗方案推荐使用。为进一步促进临床合理、规范使用尿毒清颗粒,特制定本指南。

Clin Kidney J:uACR与eGFR联合筛查CKD效果更好,年轻和女性隐匿肾损伤检出率提升

uACR联合eGFR筛查可显著提高CKD早期检出率(较单纯eGFR提升7.6%),尤其在年轻及女性群体中揭示隐匿性肾损伤。

Clin Kidney J:CKD患者肾功能越差、RAASi治疗越易患高钾血症,并增加住院和死亡风险

CKD患者高钾血症患病率随肾功能恶化及RAASi使用显著升高,且与住院率、医疗成本及死亡率增加密切相关。

Clin Kidney J:透析CKD患者癌症发病率高出35%,肾功能越差风险越大

慢性肾脏病(CKD)是全球日益严重的健康威胁,影响约10%的成年人。近年研究表明,CKD患者癌症死亡率显著升高,但其癌症发病率是否高于普通人群仍存在争议。现有研究多基于透析或移植患者数据,而针对非透析

Clin Kidney J | 丹麦CKD流行现状:近一成成年人患病,新发患者五年死亡率达四分之一

丹麦CKD的流行病学特征:近1/10成年人存在CKD,新发患者中1/4在5年内死亡。

2015慢性肾脏病评估及管理临床实践指南解读——从 K/DOQI 到 KDIGO

国际肾脏病学会(ISN,International Society of Nephrology) · 2016-04-25

慢性肾脏病筛查诊断及防治指南

肾脏病相关专家小组(统称) · 2017-01-30

HIV感染合并慢性肾脏病患者管理专家共识

中国感染病相关专家组(统称) · 2017-06-15